AI brief of an SEC Form 8-K · Healthcare Realty Trust (HR)

Healthcare Realty names Daniel Gabbay CFO as Austen Helfrich departs

Neutral Impact 4 of 5 leadership Written later

Healthcare Realty Trust appointed Daniel Gabbay, a former RBC Capital Markets managing director covering healthcare REITs, as executive vice president and chief financial officer effective January 12, 2026. CFO Austen Helfrich is leaving the same day, and the company expects to record a charge of approximately $5 million for the quarter ending March 31, 2026, related to his separation. The company said there is no change to its previously issued 2025 Normalized FFO guidance.

Key points

  • Daniel Gabbay becomes EVP and CFO effective January 12, 2026; he previously served as a managing director at RBC Capital Markets and Barclays.
  • Austen Helfrich, CFO since October 2024, departs effective January 12, 2026, under the termination other than for cause provisions of his employment agreement.
  • Gabbay's employment terms include a $500,000 base salary, a $625,000 target annual cash incentive, $1,375,000 in 2026 target equity awards, a $2,750,000 make-whole restricted stock award and $300,000 in relocation benefits.
  • The company expects a charge of approximately $5 million for the quarter ended March 31, 2026, tied to Helfrich's separation.

The filing

CompanyHealthcare Realty Trust (HR)
Form8-K, current report
Filed with the SECJan 7, 2026, 4:16 PM ET
Accession number0001360604-26-000009

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.